The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes

Primary Care Diabetes

Volumn 6, Issue 2, 2012, Pages 157-161

  King, Dana E ^a   Player, Marty ^a   Everett, Charles J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ADMA; Cardiovascular; Diabetes; Isoprostanes; Nitric oxide; Pioglitazone

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PIOGLITAZONE; PLACEBO;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT DURATION; TREATMENT OUTCOME;

ACADEMIC MEDICAL CENTERS; ARGININE; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DINOPROST; F2-ISOPROSTANES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NITRATES; NITRITES; OXIDATIVE STRESS; PROSPECTIVE STUDIES; SOUTH CAROLINA; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861335857     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2011.06.002     Document Type: Article

References (26)

1. R.H. Böger, and E.Y. Ron l-Arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor Altern. Med. Rev. 10 1 2005 14 23
2. C. Zoccali Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move J. Hypertens. 24 4 2006 611 619
3. S. Ueda, S. Yamagishi, and Y. Matsumoto Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease Clin. Exp. Nehprol. 11 2 2007 115 121
4. E. Cavusoglu, C. Ruwende, and V. Chopra Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography Atherosclerosis 2009 [Epub ahead of print]
5. K. Krzyzanowska, F. Mittermayer, M. Wolzt, and G. Schernthaner Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes Diabetes Care 30 7 2007 1834 1839
6. E. Schwedhelm, R. Maas, and R. Freese Pharmacokinetic and pharmacodynamic properties of oral l-citrulline and l-arginine: impact on nitric oxide metabolism Br. J. Clin. Pharmacol. 65 1 2008 51 59
7. D.E. King, and M. DeLegge The impact of fiber supplementation on ADMA levels Nutr. Clin. Pract. 24 1 2009 80 83
8. S. Yasuda, H. Kobayashi, and M. Iwasa Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase and Akt, and eNOS pathway in a rabbit model of myocardial infarction Am. J. Physiol. Heart Circ. Physiol. 296 5 2009 H1558 H1565
9. T. Imanishi, A. Kuroi, and H. Ikejima Effects of pioglitazone on nitric oxide bioavailability measured using a catheter-type nitric oxide sensor in angiotensin II-infusion rabbit Hypertens. Res. 31 1 2008 117 125
10. R. Saiki, M. Okazaki, and S. Iwai Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution J. Pharmacol. Sci. 105 2 2007 157 167
11. S. Llorens, Y. Mendizabal, and E. Nava Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension Eur. J. Pharmacol. 575 1-3 2007 105-
12. S. Wakino, K. Hayashi, and S. Tatematsu Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats Hypertens. Res. 28 3 2005 255 262
13. C. Staniloae, V. Mandadi, and D. Kurian Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease Cardiology 108 2007 164 169
14. M. Fernandez, C. Triplitt, and E. Wajcberg Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms Diabetes Care 31 1 2008 121 127
15. H. Sourij, R. Zweiker, and T.C. Wascher Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes Diabetes Care 29 5 2006 1039 1045
16. H. Maegawa, Y. Nishio, and K. Nakao Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes Endocr. J. 54 4 2007 613 618
17. C. Staniloae, V. Mandadi, and D. Kurian Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease Cardiology 108 3 2006 164 169
18. Y. Mori, Y. Itoh, T. Obata, and N. Tajima Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes Endocrine 29 1 2006 143 148
19. F. Schulze, H. Lenzen, and C. Hanefeld Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study Am. Heart J. 152 3 2006 493.e1-8
20. F. Schulze, R. Wesemann, and E. Schwedhelm Determination of asymmetric dimethylarginine (ADMA) by a novel ELISA assay Clin. Chem. Lab. Med. 42 12 2004 1377 1383
21. E. Devangelio, F. Santilli, and P. Formoso Soluble RAGE in type 2 diabetes: association with oxidative stress Free Radic. Biol. Med. 43 4 2007 511 518
22. J.C. Oates, and Gilkeson GS The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus Clin. Immunol. 121 3 2006 243 250
23. J.C. Oates, and Gilkeson GS Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice J. Investig. Med. 52 1 2004 62 71
24. T. Horio, M. Suzuki, and I. Takamisawa Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension Am. J. Hypertens. 18 12 2005 1626 1630
25. U. Campia, L.A. Matuskey, and J.A. Panza Peroxisome proliferator- activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors Circulation 113 6 2006 867 875
26. A.S. Kelly, A.M. Thelen, D.R. Kaiser, J.M. Gonzalez-Campov, and A.J. Bank Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Vasc. Med. 12 4 2007 311 318